Pub Date : 2024-06-17DOI: 10.1016/j.ijcchd.2024.100522
Wouter J. van Genuchten , Eva van den Bosch , Saskia E. Luijnenburg , Vivian P. Kamphuis , Jolien W. Roos-Hesselink , Beatrijs Bartelds , Arno A.W. Roest , Johannes M.P.J. Breur , Nico A. Blom , Eric Boersma , Laurens P. Koopman , Willem A. Helbing
Introduction
Patients after surgical correction of Tetralogy of Fallot (ToF) often show adverse cardiac remodeling. To better understand the underlying biological processes, we studied the relation between changes in blood biomarkers and changes in biventricular size and function as assessed by cardiac magnetic resonance imaging (CMR).
Methods
This study included 50 ToF patients, who underwent blood biomarker and CMR analysis at least twice between 2002 and 2018.34 (68 %) of these patients were male. Patients had an average age of 16.1 at first visit. Biomarkers were chosen based on earlier research by our group and included: NT-proBNP, ST2, GDF-15, DLK-1, IGFBP-1/7, and FABP-4. Pearson correlations coefficients (rpearson) were determined to quantify the relationship between changes in biomarkers and CMR measurements.
Results
For changes in parameters of right ventricular (RV) size significant correlations were observed with changes in NT-proBNP, ST-2, GDF-15, IGFBP7 and FABP-4 (rpearson between 0.28 and 0.51). Correlations with NT-proBNP were driven by changes in RV size induced by pulmonary valve replacement (n = 9). For LV serial size changes, significant correlations were noted with changes in NT-pro-BNP, ST-2, GDF-15 and FABP-4 (rpearson between 0.32 and 0.52).
Conclusion
In clinically stable ToF patients changes in right and left ventricular size and function correlated with alterations in blood biomarkers of inflammation and immune response to stress.
{"title":"Changes in blood biomarkers correlate with changes in cardiac size and function in patients with tetralogy of Fallot","authors":"Wouter J. van Genuchten , Eva van den Bosch , Saskia E. Luijnenburg , Vivian P. Kamphuis , Jolien W. Roos-Hesselink , Beatrijs Bartelds , Arno A.W. Roest , Johannes M.P.J. Breur , Nico A. Blom , Eric Boersma , Laurens P. Koopman , Willem A. Helbing","doi":"10.1016/j.ijcchd.2024.100522","DOIUrl":"https://doi.org/10.1016/j.ijcchd.2024.100522","url":null,"abstract":"<div><h3>Introduction</h3><p>Patients after surgical correction of Tetralogy of Fallot (ToF) often show adverse cardiac remodeling. To better understand the underlying biological processes, we studied the relation between changes in blood biomarkers and changes in biventricular size and function as assessed by cardiac magnetic resonance imaging (CMR).</p></div><div><h3>Methods</h3><p>This study included 50 ToF patients, who underwent blood biomarker and CMR analysis at least twice between 2002 and 2018.34 (68 %) of these patients were male. Patients had an average age of 16.1 at first visit. Biomarkers were chosen based on earlier research by our group and included: NT-proBNP, ST2, GDF-15, DLK-1, IGFBP-1/7, and FABP-4. Pearson correlations coefficients (r<sub>pearson</sub>) were determined to quantify the relationship between changes in biomarkers and CMR measurements.</p></div><div><h3>Results</h3><p>For changes in parameters of right ventricular (RV) size significant correlations were observed with changes in NT-proBNP, ST-2, GDF-15, IGFBP7 and FABP-4 (r<sub>pearson</sub> between 0.28 and 0.51). Correlations with NT-proBNP were driven by changes in RV size induced by pulmonary valve replacement (n = 9). For LV serial size changes, significant correlations were noted with changes in NT-pro-BNP, ST-2, GDF-15 and FABP-4 (r<sub>pearson</sub> between 0.32 and 0.52).</p></div><div><h3>Conclusion</h3><p>In clinically stable ToF patients changes in right and left ventricular size and function correlated with alterations in blood biomarkers of inflammation and immune response to stress.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"17 ","pages":"Article 100522"},"PeriodicalIF":0.8,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000314/pdfft?md5=178b53ad5a8b101aa2be291e602776a3&pid=1-s2.0-S2666668524000314-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141487031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-12DOI: 10.1016/j.ijcchd.2024.100519
Katarina Zeder , Teresa Sassmann , Vasile Foris , Philipp Douschan , Horst Olschewski , Gabor Kovacs
Rationale
Severe pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) is currently defined by an elevated mean pulmonary arterial pressure and strongly elevated pulmonary vascular resistance >5 wood units. Clinically, these patients show a male predominance, and usually present with very severe dyspnea, severe hypoxemia, strongly decreased exercise capacity and poor prognosis, even though the clinical picture is frequently associated with less severe airflow obstruction. Explanted lung samples of patients with COPD and severe PH show severe remodeling of small pulmonary arterioles, predominantly in the intima and media of the vessels. In this concise review, we discuss the clinical and histopathological evidence of severe PH in COPD.
{"title":"Severe pulmonary hypertension in chronic obstructive pulmonary disease – From clinical perspective to histological evidence","authors":"Katarina Zeder , Teresa Sassmann , Vasile Foris , Philipp Douschan , Horst Olschewski , Gabor Kovacs","doi":"10.1016/j.ijcchd.2024.100519","DOIUrl":"10.1016/j.ijcchd.2024.100519","url":null,"abstract":"<div><h3>Rationale</h3><p>Severe pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD) is currently defined by an elevated mean pulmonary arterial pressure and strongly elevated pulmonary vascular resistance >5 wood units. Clinically, these patients show a male predominance, and usually present with very severe dyspnea, severe hypoxemia, strongly decreased exercise capacity and poor prognosis, even though the clinical picture is frequently associated with less severe airflow obstruction. Explanted lung samples of patients with COPD and severe PH show severe remodeling of small pulmonary arterioles, predominantly in the intima and media of the vessels. In this concise review, we discuss the clinical and histopathological evidence of severe PH in COPD.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"17 ","pages":"Article 100519"},"PeriodicalIF":0.8,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000284/pdfft?md5=569abcd135629eb94eb0ef63a5a90c9b&pid=1-s2.0-S2666668524000284-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141399574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-10DOI: 10.1016/j.ijcchd.2024.100520
Ranjan Banerjee , Alexander R. Opotowsky
Longstanding left-to-right shunting associated with congenital heart disease (CHD) can ultimately lead to pulmonary vascular remodeling, pulmonary arterial hypertension, and shunt reversal, the hallmark feature of Eisenmenger Syndrome (ES). ES is a multisystem disease, with hematologic, cardiovascular, renal, neurologic, immune, and other manifestations, each of which inform its management. Many of the most distinct and clinically important consequences relate to chronic hypoxemia. The incidence of ES in in countries with access to pediatric cardiology and cardiac surgery services has declined in recent decades, due to earlier diagnosis and intervention for CHD. Moreover, in the era of disease targeting therapies (DTT), ES appears to be associated with better quality of life and less limiting symptoms. In addition, observational studies suggest that these therapies, alone and in combination, may be associated with improved survival. Despite these developments, ES mortality remains high, with heart failure being the most common cause of death. In this review, we discuss the pathophysiology of ES, the evolving understanding of risk stratification, as well as recent progress in pharmacologic and surgical management. Ultimately, despite strides in understanding and management of this complex disease, significant knowledge gaps remain.
与先天性心脏病(CHD)相关的长期左向右分流最终会导致肺血管重塑、肺动脉高压和分流逆转,这是艾森曼格综合征(ES)的标志性特征。艾森曼格综合征是一种多系统疾病,具有血液、心血管、肾脏、神经、免疫和其他方面的表现,其中每一种表现都为其治疗提供了依据。许多最明显和临床上最重要的后果都与慢性低氧血症有关。近几十年来,由于对先天性心脏病的早期诊断和干预,在能够获得儿童心脏病学和心脏外科服务的国家,ES 的发病率有所下降。此外,在疾病靶向治疗(DTT)时代,ES 似乎与更好的生活质量和更少的限制性症状相关。此外,观察性研究表明,这些疗法无论是单独使用还是联合使用,都能提高患者的生存率。尽管取得了这些进展,但 ES 的死亡率仍然很高,心力衰竭是最常见的死亡原因。在这篇综述中,我们将讨论 ES 的病理生理学、对风险分层不断发展的认识以及药物和手术治疗的最新进展。归根结底,尽管对这种复杂疾病的理解和管理取得了长足进步,但仍然存在巨大的知识差距。
{"title":"Update on Eisenmenger syndrome – Review of pathophysiology and recent progress in risk assessment and management","authors":"Ranjan Banerjee , Alexander R. Opotowsky","doi":"10.1016/j.ijcchd.2024.100520","DOIUrl":"10.1016/j.ijcchd.2024.100520","url":null,"abstract":"<div><p>Longstanding left-to-right shunting associated with congenital heart disease (CHD) can ultimately lead to pulmonary vascular remodeling, pulmonary arterial hypertension, and shunt reversal, the hallmark feature of Eisenmenger Syndrome (ES). ES is a multisystem disease, with hematologic, cardiovascular, renal, neurologic, immune, and other manifestations, each of which inform its management. Many of the most distinct and clinically important consequences relate to chronic hypoxemia. The incidence of ES in in countries with access to pediatric cardiology and cardiac surgery services has declined in recent decades, due to earlier diagnosis and intervention for CHD. Moreover, in the era of disease targeting therapies (DTT), ES appears to be associated with better quality of life and less limiting symptoms. In addition, observational studies suggest that these therapies, alone and in combination, may be associated with improved survival. Despite these developments, ES mortality remains high, with heart failure being the most common cause of death. In this review, we discuss the pathophysiology of ES, the evolving understanding of risk stratification, as well as recent progress in pharmacologic and surgical management. Ultimately, despite strides in understanding and management of this complex disease, significant knowledge gaps remain.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"17 ","pages":"Article 100520"},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000296/pdfft?md5=d074ac28530dadb3c85fa2b2b9bf4d22&pid=1-s2.0-S2666668524000296-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141406307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-04DOI: 10.1016/j.ijcchd.2024.100518
Lucía Cobarro, Santiago Jiménez-Valero, Federico Gutiérrez-Larraya, Carlos Merino, Pablo Merás, José Ruiz-Cantador, Enrique Balbacid, Isabel D. Poveda, Sandra O. Rosillo, Juan Caro-Codón, Alfonso Jurado-Román, Raúl Moreno
Background
Obstructive complications in the Fontan circulation pose significant risks to affected patients. Traditional management strategies may be insufficient, necessitating innovative treatment approaches. This case report discusses the use of the FlowTriever Retrieval System for percutaneous aspiration thrombectomy in a patient with a history of Fontan procedure who developed conduit obstruction due to thrombus formation.
Case report
A 28-year-old male with a history of double inlet left ventricle and previous Fontan procedure presented with progressive dyspnea. Despite initial thrombectomy for high-risk pulmonary embolism, thrombi remained in the Fontan conduit and inferior vena cava. The patient remained hemodynamically unstable. Imaging confirmed thrombosis of the extracardiac conduit. An innovative percutaneous approach using the FlowTriever system successfully restored conduit flow and removed thrombus. Subsequent stenting addressed residual stenosis. Post-intervention, the patient showed remarkable clinical improvement. There were no procedure-related complications. He was discharged on an optimized anticoagulation regimen and remained asymptomatic during follow-up.
Conclusion
This case demonstrates the efficacy of the FlowTriever Retrieval System in managing complex thrombotic obstructions in Fontan circulation, which not only effectively resolved the obstruction but also maintained haemodynamic stability, thus highlighting its potential to enhance current treatment modalities for such congenital heart conditions.
背景丰坦循环阻塞性并发症给患者带来巨大风险。传统的治疗策略可能不足以解决问题,因此需要创新的治疗方法。本病例报告讨论了使用 FlowTriever Retrieval System 经皮抽吸血栓切除术治疗一名因血栓形成导致导管阻塞的丰坦手术史患者的情况。尽管最初对高危肺栓塞进行了血栓切除术,但血栓仍残留在丰坦导管和下腔静脉中。患者血流动力学仍不稳定。影像学检查证实心外导管血栓形成。使用FlowTriever系统的创新经皮方法成功恢复了导管血流并清除了血栓。随后的支架植入术解决了残余狭窄问题。干预后,患者的临床症状明显改善。没有出现与手术相关的并发症。结论本病例展示了 FlowTriever Retrieval 系统在处理丰坦循环复杂血栓性阻塞方面的疗效,不仅有效地解决了阻塞问题,还保持了血流动力学的稳定,从而凸显了该系统在改善此类先天性心脏病现有治疗方法方面的潜力。
{"title":"Novel percutaneous aspiration thrombectomy in Fontan conduit obstruction with cardiogenic shock. Case report","authors":"Lucía Cobarro, Santiago Jiménez-Valero, Federico Gutiérrez-Larraya, Carlos Merino, Pablo Merás, José Ruiz-Cantador, Enrique Balbacid, Isabel D. Poveda, Sandra O. Rosillo, Juan Caro-Codón, Alfonso Jurado-Román, Raúl Moreno","doi":"10.1016/j.ijcchd.2024.100518","DOIUrl":"https://doi.org/10.1016/j.ijcchd.2024.100518","url":null,"abstract":"<div><h3>Background</h3><p>Obstructive complications in the Fontan circulation pose significant risks to affected patients. Traditional management strategies may be insufficient, necessitating innovative treatment approaches. This case report discusses the use of the FlowTriever Retrieval System for percutaneous aspiration thrombectomy in a patient with a history of Fontan procedure who developed conduit obstruction due to thrombus formation.</p></div><div><h3>Case report</h3><p>A 28-year-old male with a history of double inlet left ventricle and previous Fontan procedure presented with progressive dyspnea. Despite initial thrombectomy for high-risk pulmonary embolism, thrombi remained in the Fontan conduit and inferior vena cava. The patient remained hemodynamically unstable. Imaging confirmed thrombosis of the extracardiac conduit. An innovative percutaneous approach using the FlowTriever system successfully restored conduit flow and removed thrombus. Subsequent stenting addressed residual stenosis. Post-intervention, the patient showed remarkable clinical improvement. There were no procedure-related complications. He was discharged on an optimized anticoagulation regimen and remained asymptomatic during follow-up.</p></div><div><h3>Conclusion</h3><p>This case demonstrates the efficacy of the FlowTriever Retrieval System in managing complex thrombotic obstructions in Fontan circulation, which not only effectively resolved the obstruction but also maintained haemodynamic stability, thus highlighting its potential to enhance current treatment modalities for such congenital heart conditions.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"17 ","pages":"Article 100518"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000272/pdfft?md5=08b7788478494a559eb013035dc41572&pid=1-s2.0-S2666668524000272-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-01DOI: 10.1016/j.ijcchd.2024.100513
Stefano Rodolfi , Voon H. Ong , Christopher P. Denton
Connective tissue disease associated pulmonary arterial hypertension (CTD-PAH) has benefited from the major treatment advances that have occurred within pulmonary hypertension over the past three decades. Inclusion of CTD-PAH cases in pivotal clinical trials led to regulatory approval and drug availability. This has improved outcomes but there are additional challenges for management. First, the multifaceted co-morbidity related to the associated CTD needs treatment alongside PAH and may impact on diagnosis and evaluation of treatment response. Secondary, cardiac involvement, interstitial lung disease and predisposition to thromboembolism in CTD may lead to compound phenotypes where PH has multiple mechanisms as well as precapillary pulmonary vasculopathy of PAH. In general, especially for systemic sclerosis, CTD-PAH has worse long-term survival than idiopathic or familial PAH. However, CTD also present an opportunity for screening and early detection and treatment for associated PAH, and this may in the future be a major advantage over idiopathic disease where presentation inevitable only occurs at symptomatic stages and diagnosis may be delayed. This article reviews and summarises some of the recent developments in investigation and management of CTD-PAH.
{"title":"Recent developments in connective tissue disease associated pulmonary arterial hypertension","authors":"Stefano Rodolfi , Voon H. Ong , Christopher P. Denton","doi":"10.1016/j.ijcchd.2024.100513","DOIUrl":"10.1016/j.ijcchd.2024.100513","url":null,"abstract":"<div><p>Connective tissue disease associated pulmonary arterial hypertension (CTD-PAH) has benefited from the major treatment advances that have occurred within pulmonary hypertension over the past three decades. Inclusion of CTD-PAH cases in pivotal clinical trials led to regulatory approval and drug availability. This has improved outcomes but there are additional challenges for management. First, the multifaceted co-morbidity related to the associated CTD needs treatment alongside PAH and may impact on diagnosis and evaluation of treatment response. Secondary, cardiac involvement, interstitial lung disease and predisposition to thromboembolism in CTD may lead to compound phenotypes where PH has multiple mechanisms as well as precapillary pulmonary vasculopathy of PAH. In general, especially for systemic sclerosis, CTD-PAH has worse long-term survival than idiopathic or familial PAH. However, CTD also present an opportunity for screening and early detection and treatment for associated PAH, and this may in the future be a major advantage over idiopathic disease where presentation inevitable only occurs at symptomatic stages and diagnosis may be delayed. This article reviews and summarises some of the recent developments in investigation and management of CTD-PAH.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"16 ","pages":"Article 100513"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000223/pdfft?md5=6a51b0bf0b4469ad16ab81449b6c7dc6&pid=1-s2.0-S2666668524000223-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140781172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Exercise capacity is reduced in patients with a Fontan circulation compared to their healthy peers secondary to altered haemodynamics of the Fontan circulation. Cardiopulmonary exercise testing is routinely used in Fontan patients to assess their cardiopulmonary response to exercise and help guide management decisions, however their results are routinely compared to normative data derived from healthy individuals.
Method
Using data available from the Pediatric Heart Network, we performed a retrospective study to derive Fontan-specific normative values in a subgroup of well-functioning adolescent patients. We utilised results from the Congenital Heart Adolescent and Teenager (CHAT) Questionnaire to classify patients into well-functioning and lower-functioning groups.
Results
We generated Fontan-specific regression equations in adolescent male and females for normative values of peak oxygen consumption (VO2), maximal workload and VO2 at anaerobic threshold.
Conclusion
We propose that Fontan-specific normative values are a more useful comparison than healthy normative data due to the known circulatory limitations of the Fontan circulation and will assist in management decision and prognostication.
{"title":"Deriving fontan-specific normative exercise data from well-functioning adolescents","authors":"Karina Laohachai , Annabel Webb , Rachael Cordina , Yves d’Udekem , Robert Weintraub , Kathryn Rice , Julian Ayer","doi":"10.1016/j.ijcchd.2024.100514","DOIUrl":"https://doi.org/10.1016/j.ijcchd.2024.100514","url":null,"abstract":"<div><h3>Background</h3><p>Exercise capacity is reduced in patients with a Fontan circulation compared to their healthy peers secondary to altered haemodynamics of the Fontan circulation. Cardiopulmonary exercise testing is routinely used in Fontan patients to assess their cardiopulmonary response to exercise and help guide management decisions, however their results are routinely compared to normative data derived from healthy individuals.</p></div><div><h3>Method</h3><p>Using data available from the Pediatric Heart Network, we performed a retrospective study to derive Fontan-specific normative values in a subgroup of well-functioning adolescent patients. We utilised results from the Congenital Heart Adolescent and Teenager (CHAT) Questionnaire to classify patients into well-functioning and lower-functioning groups.</p></div><div><h3>Results</h3><p>We generated Fontan-specific regression equations in adolescent male and females for normative values of peak oxygen consumption (VO<sub>2</sub>), maximal workload and VO<sub>2</sub> at anaerobic threshold.</p></div><div><h3>Conclusion</h3><p>We propose that Fontan-specific normative values are a more useful comparison than healthy normative data due to the known circulatory limitations of the Fontan circulation and will assist in management decision and prognostication.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"17 ","pages":"Article 100514"},"PeriodicalIF":0.8,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000235/pdfft?md5=e3a115dba2d725a5a3d72094edf6d40c&pid=1-s2.0-S2666668524000235-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141487030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rates of morbidity and mortality are high in the setting of Fontan physiology and effective medical therapies are not well-established. Clinical trials assessing phosophodiesterase-5-inhibitors, such as sildenafil, have not demonstrated major benefit in patients with a Fontan-type circulation but have only included stable, well-functioning people.
Methods
We sought to retrospectively characterize the people followed by the ANZ Fontan Registry prescribed sildenafil >30 days post Fontan-surgery.
Results
Of 1867 individuals, 19 (1 %) were prescribed sildenafil and met inclusion criteria; 12 (63 %) were female. Age at commencement was 9 years (IQR 13.5). Reasons for commencement were Fontan failure with elevated Fontan pressure (n = 4), failure without elevated pressure (n = 4), elevated pressure without failure (n = 6), failure symptoms without invasive assessment (n = 3) and pulmonary arterio-venous malformations (n = 2). At baseline hemodynamic study (n = 16) median Fontan pressure was 15.5 mmHg (IQR 3.1) and PVRi was 2.3 WU*m2 (IQR 1.6). Improvement in the clinical indication was noted in 11/19 (58 %). In the subset in whom sildenafil was commenced with PVRi >2 WU*m2 6/7 (86 %) improved clinically. PVRi decreased by 1.8 WU*m2 (IQR 1.0, n = 5, p = 0.03) on treatment in this group, compared with the <2 WU*m2 group which increased by 0.3 WU*m2 (IQR 0.2, n = 3, p = 0.01).
Conclusions
Some individuals with a Fontan circulation may benefit from sildenafil. Adequately designed clinical trials are needed.
{"title":"A retrospective review of sildenafil in the Australia and New Zealand Fontan registry: indications and treatment responses","authors":"Phidias Rueter , Mathilde O'Dell , David Celermajer , Clare O'Donnell , Julian Ayer , Yves d’Udekem , Rachael Cordina","doi":"10.1016/j.ijcchd.2024.100511","DOIUrl":"https://doi.org/10.1016/j.ijcchd.2024.100511","url":null,"abstract":"<div><h3>Introduction</h3><p>Rates of morbidity and mortality are high in the setting of Fontan physiology and effective medical therapies are not well-established. Clinical trials assessing phosophodiesterase-5-inhibitors, such as sildenafil, have not demonstrated major benefit in patients with a Fontan-type circulation but have only included stable, well-functioning people.</p></div><div><h3>Methods</h3><p>We sought to retrospectively characterize the people followed by the ANZ Fontan Registry prescribed sildenafil >30 days post Fontan-surgery.</p></div><div><h3>Results</h3><p>Of 1867 individuals, 19 (1 %) were prescribed sildenafil and met inclusion criteria; 12 (63 %) were female. Age at commencement was 9 years (IQR 13.5). Reasons for commencement were Fontan failure with elevated Fontan pressure (n = 4), failure without elevated pressure (n = 4), elevated pressure without failure (n = 6), failure symptoms without invasive assessment (n = 3) and pulmonary arterio-venous malformations (n = 2). At baseline hemodynamic study (n = 16) median Fontan pressure was 15.5 mmHg (IQR 3.1) and PVRi was 2.3 WU*m<sup>2</sup> (IQR 1.6). Improvement in the clinical indication was noted in 11/19 (58 %). In the subset in whom sildenafil was commenced with PVRi >2 WU*m<sup>2</sup> 6/7 (86 %) improved clinically. PVRi decreased by 1.8 WU*m<sup>2</sup> (IQR 1.0, n = 5, p = 0.03) on treatment in this group, compared with the <2 WU*m<sup>2</sup> group which increased by 0.3 WU*m<sup>2</sup> (IQR 0.2, n = 3, p = 0.01).</p></div><div><h3>Conclusions</h3><p>Some individuals with a Fontan circulation may benefit from sildenafil. Adequately designed clinical trials are needed.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"16 ","pages":"Article 100511"},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266666852400020X/pdfft?md5=228bd89a2391d5d2d63f93d651b27015&pid=1-s2.0-S266666852400020X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140632890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-09DOI: 10.1016/j.ijcchd.2024.100510
Jason Chami , Calum Nicholson , David Baker , Rachael Cordina , Geoff Strange , David S. Celermajer
Background
In order to manage a class of diseases as broad as congenital heart disease (CHD), multiple “manually generated” classification systems defining CHDs as mild, moderate and severe have been developed and used to good effect. As databases have grown, however, such “manual” complexity scoring has become infeasible. Though past attempts have been made to determine CHD complexity algorithmically using a list of diagnoses alone, missing data and lack of procedural information have been significant limitations.
Methods
We built an algorithm that can stratify the complexity of patients with CHD by integrating their diagnoses with a list of their previous procedures. Specific procedures which address a missing diagnosis or imply a certain operative status were used to supplement the diagnosis list. To verify this algorithm, CHD specialists manually checked the classification of 100 children and 100 adults across four hospitals in Australia.
Results
Our algorithm was 99.5% accurate in the manually checked cohort (100% in children and 99% in adults) and was able to automatically classify more than 90% of a cohort of over 24,000 CHD patients, including 92.5% of children (vs 84.4% without procedures, p < 0.0001) and 91.1% of adults (vs 70.4% without procedures; p < 0.0001).
Conclusions
CHD complexity scoring is significantly improved by access to procedural history and can be automatically calculated with high accuracy.
{"title":"Improved complexity stratification in congenital heart disease; the impact of including procedural data on accuracy and reliability","authors":"Jason Chami , Calum Nicholson , David Baker , Rachael Cordina , Geoff Strange , David S. Celermajer","doi":"10.1016/j.ijcchd.2024.100510","DOIUrl":"https://doi.org/10.1016/j.ijcchd.2024.100510","url":null,"abstract":"<div><h3>Background</h3><p>In order to manage a class of diseases as broad as congenital heart disease (CHD), multiple “manually generated” classification systems defining CHDs as mild, moderate and severe have been developed and used to good effect. As databases have grown, however, such “manual” complexity scoring has become infeasible. Though past attempts have been made to determine CHD complexity algorithmically using a list of diagnoses alone, missing data and lack of procedural information have been significant limitations.</p></div><div><h3>Methods</h3><p>We built an algorithm that can stratify the complexity of patients with CHD by integrating their diagnoses with a list of their previous procedures. Specific procedures which address a missing diagnosis or imply a certain operative status were used to supplement the diagnosis list. To verify this algorithm, CHD specialists manually checked the classification of 100 children and 100 adults across four hospitals in Australia.</p></div><div><h3>Results</h3><p>Our algorithm was 99.5% accurate in the manually checked cohort (100% in children and 99% in adults) and was able to automatically classify more than 90% of a cohort of over 24,000 CHD patients, including 92.5% of children (vs 84.4% without procedures, p < 0.0001) and 91.1% of adults (vs 70.4% without procedures; p < 0.0001).</p></div><div><h3>Conclusions</h3><p>CHD complexity scoring is significantly improved by access to procedural history and can be automatically calculated with high accuracy.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"16 ","pages":"Article 100510"},"PeriodicalIF":0.0,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000193/pdfft?md5=3a6f9381f896350254d42345774b6253&pid=1-s2.0-S2666668524000193-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-05DOI: 10.1016/j.ijcchd.2024.100512
C. Pelosi , R.M. Kauling , J.A.A.E. Cuypers , E.M.W.J. Utens , A.E. van den Bosch , W.A. Helbing , J.S. Legerstee , J.W. Roos-Hesselink
Background
Sports are associated with numerous physiological and psychological benefits. However, it is unclear to what extent adults with congenital heart disease(CHD) participate in sports and whether this is safe. Furthermore, little is known about lifestyle habits in this group.
Methods
Consecutive patients diagnosed with atrial septal defect, ventricular septal defect, pulmonary stenosis, tetralogy of Fallot and transposition of the great arteries who underwent open-heart surgery during childhood between 1968 and 1980 were included in a longitudinal follow-up study. Patients underwent cardiological investigations every 10 years and completed a questionnaire regarding sports participation in 2011 and in 2021.
Results
Of the 2021 cohort(n = 204, mean age:50 years, 46%female), 49% participated in sports. Compared to the general Dutch population they invested less time in sport(female: p = 0.03, male: p = 0.03). Patients participating in sports had better exercise capacity (p < 0.001) and lower average heart rate(p < 0.001). Patients engaged in sports reported better physical and mental health when compared to the norm and non-sporters. Mortality and cardiac events did not differ significantly between the 2 groups. Finally, no difference in lifestyle was found between adults with CHD and the general population, only smoking was less often reported among adults with CHD(p = 0.036).
Conclusions
Adults with CHD are significantly less involved in sports than their peers. Patients who were engaged in sports had better physical and mental health compared to those who were not. Sport participation was associated with lower heart rate and better exercise capacity. No negative effect in terms of cardiac events was observed in sporters. No signs of bad lifestyle were observed in adults with CHD.
{"title":"Sports participation and lifestyle in middle-aged adults with congenital heart disease","authors":"C. Pelosi , R.M. Kauling , J.A.A.E. Cuypers , E.M.W.J. Utens , A.E. van den Bosch , W.A. Helbing , J.S. Legerstee , J.W. Roos-Hesselink","doi":"10.1016/j.ijcchd.2024.100512","DOIUrl":"10.1016/j.ijcchd.2024.100512","url":null,"abstract":"<div><h3>Background</h3><p>Sports are associated with numerous physiological and psychological benefits. However, it is unclear to what extent adults with congenital heart disease(CHD) participate in sports and whether this is safe. Furthermore, little is known about lifestyle habits in this group.</p></div><div><h3>Methods</h3><p>Consecutive patients diagnosed with atrial septal defect, ventricular septal defect, pulmonary stenosis, tetralogy of Fallot and transposition of the great arteries who underwent open-heart surgery during childhood between 1968 and 1980 were included in a longitudinal follow-up study. Patients underwent cardiological investigations every 10 years and completed a questionnaire regarding sports participation in 2011 and in 2021.</p></div><div><h3>Results</h3><p>Of the 2021 cohort(n = 204, mean age:50 years, 46%female), 49% participated in sports. Compared to the general Dutch population they invested less time in sport(female: p = 0.03, male: p = 0.03). Patients participating in sports had better exercise capacity (p < 0.001) and lower average heart rate(p < 0.001). Patients engaged in sports reported better physical and mental health when compared to the norm and non-sporters. Mortality and cardiac events did not differ significantly between the 2 groups. Finally, no difference in lifestyle was found between adults with CHD and the general population, only smoking was less often reported among adults with CHD(p = 0.036).</p></div><div><h3>Conclusions</h3><p>Adults with CHD are significantly less involved in sports than their peers. Patients who were engaged in sports had better physical and mental health compared to those who were not. Sport participation was associated with lower heart rate and better exercise capacity. No negative effect in terms of cardiac events was observed in sporters. No signs of bad lifestyle were observed in adults with CHD.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"17 ","pages":"Article 100512"},"PeriodicalIF":0.8,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000211/pdfft?md5=994c27a7c388dc664bcf4902fd6dd589&pid=1-s2.0-S2666668524000211-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140794398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-30DOI: 10.1016/j.ijcchd.2024.100507
Marit Sandberg , Tatiana Fomina , Ferenc Macsali , Gottfried Greve , Mette-Elise Estensen , Nina Øyen , Elisabeth Leirgul
Background
More women with congenital heart disease (CHD) reach reproductive age, but little is known of their success in having children. We investigated time trends of CHD in women of reproductive age and maternal CHD in childbirth and compared birth rates in women with CHD to birth rates in women without heart disease.
Methods and results
In a national cohort, we combined information from five registries in Norway 1994–2014. Among 1,644,650 women aged 15–45 years, 5672 had CHD. Among 1,183,851 childbirths, 3504 were registered with maternal CHD. The prevalences of mild and moderate/severe CHD in women increased by an average of 3–4% per year 1994–2014, as did the prevalences of mild and moderate/severe maternal CHD in childbirth. Compared to women without heart disease, the likelihood of having children was similar for women with mild CHD (rate ratio 1.03, 95% confidence interval 0.97–1.09) but lower for women with moderate/severe CHD (rate ratio 0.75, 95% confidence interval 0.68–0.84). The mean number of childbirths was similar in women with mild CHD and women without heart disease (1.81 vs 1.80, p = 0.722) but lower in women with moderate/severe CHD (1.42, p < 0.001).
Conclusion
In a national cohort over two decades of women of reproductive age, the prevalence of maternal CHD in childbirth reflected the increasing prevalence of CHD in the population. Birth rates were similar for women with mild CHD and women without heart disease, whereas women with moderate/severe CHD were less likely to have children and had a lower mean number of childbirths.
{"title":"Time trends and birth rates in women with congenital heart disease; a nationwide cohort study from Norway 1994–2014","authors":"Marit Sandberg , Tatiana Fomina , Ferenc Macsali , Gottfried Greve , Mette-Elise Estensen , Nina Øyen , Elisabeth Leirgul","doi":"10.1016/j.ijcchd.2024.100507","DOIUrl":"10.1016/j.ijcchd.2024.100507","url":null,"abstract":"<div><h3>Background</h3><p>More women with congenital heart disease (CHD) reach reproductive age, but little is known of their success in having children. We investigated time trends of CHD in women of reproductive age and maternal CHD in childbirth and compared birth rates in women with CHD to birth rates in women without heart disease.</p></div><div><h3>Methods and results</h3><p>In a national cohort, we combined information from five registries in Norway 1994–2014. Among 1,644,650 women aged 15–45 years, 5672 had CHD. Among 1,183,851 childbirths, 3504 were registered with maternal CHD. The prevalences of mild and moderate/severe CHD in women increased by an average of 3–4% per year 1994–2014, as did the prevalences of mild and moderate/severe maternal CHD in childbirth. Compared to women without heart disease, the likelihood of having children was similar for women with mild CHD (rate ratio 1.03, 95% confidence interval 0.97–1.09) but lower for women with moderate/severe CHD (rate ratio 0.75, 95% confidence interval 0.68–0.84). The mean number of childbirths was similar in women with mild CHD and women without heart disease (1.81 vs 1.80, p = 0.722) but lower in women with moderate/severe CHD (1.42, p < 0.001).</p></div><div><h3>Conclusion</h3><p>In a national cohort over two decades of women of reproductive age, the prevalence of maternal CHD in childbirth reflected the increasing prevalence of CHD in the population. Birth rates were similar for women with mild CHD and women without heart disease, whereas women with moderate/severe CHD were less likely to have children and had a lower mean number of childbirths.</p></div>","PeriodicalId":73429,"journal":{"name":"International journal of cardiology. Congenital heart disease","volume":"16 ","pages":"Article 100507"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666668524000168/pdfft?md5=7324f8f4a929bacf87be178f10b268f0&pid=1-s2.0-S2666668524000168-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140400132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}